| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 10 | 2019 | 763 | 1.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 878 | 1.420 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2023 | 159 | 1.370 |
Why?
|
| Immunotherapy | 8 | 2023 | 629 | 1.360 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2016 | 295 | 1.130 |
Why?
|
| Immune Tolerance | 5 | 2017 | 337 | 1.090 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1195 | 1.080 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 1376 | 0.970 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 151 | 0.960 |
Why?
|
| B7-H1 Antigen | 6 | 2020 | 250 | 0.960 |
Why?
|
| Transplantation Conditioning | 13 | 2020 | 373 | 0.950 |
Why?
|
| Lymphoma | 4 | 2020 | 262 | 0.920 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 177 | 0.880 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2021 | 170 | 0.850 |
Why?
|
| Melanoma, Experimental | 3 | 2014 | 103 | 0.830 |
Why?
|
| Tumor Escape | 2 | 2020 | 49 | 0.800 |
Why?
|
| Antigen-Presenting Cells | 3 | 2017 | 139 | 0.790 |
Why?
|
| Graft vs Host Disease | 9 | 2020 | 365 | 0.780 |
Why?
|
| Leukemia | 4 | 2017 | 320 | 0.740 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2357 | 0.710 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1578 | 0.700 |
Why?
|
| Homeostasis | 3 | 2012 | 409 | 0.690 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 103 | 0.680 |
Why?
|
| Neoplasms | 8 | 2018 | 2897 | 0.670 |
Why?
|
| Arabinonucleosides | 3 | 2011 | 39 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2436 | 0.600 |
Why?
|
| Immune Evasion | 1 | 2017 | 33 | 0.600 |
Why?
|
| Transplantation, Homologous | 16 | 2020 | 996 | 0.560 |
Why?
|
| Immunity, Innate | 3 | 2016 | 409 | 0.540 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2013 | 261 | 0.530 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 728 | 0.530 |
Why?
|
| Hematologic Neoplasms | 5 | 2023 | 329 | 0.510 |
Why?
|
| Lymphocyte Depletion | 4 | 2017 | 97 | 0.490 |
Why?
|
| Thymus Gland | 1 | 2014 | 195 | 0.460 |
Why?
|
| CD40 Antigens | 1 | 2013 | 43 | 0.450 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 418 | 0.450 |
Why?
|
| Signal Transduction | 5 | 2017 | 3241 | 0.440 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 166 | 0.440 |
Why?
|
| Cross-Priming | 1 | 2012 | 48 | 0.420 |
Why?
|
| Graft vs Tumor Effect | 2 | 2010 | 25 | 0.410 |
Why?
|
| Animals | 21 | 2020 | 26581 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 3092 | 0.400 |
Why?
|
| B7-1 Antigen | 3 | 2016 | 75 | 0.400 |
Why?
|
| Antigen Presentation | 3 | 2020 | 209 | 0.390 |
Why?
|
| Humans | 47 | 2023 | 86601 | 0.370 |
Why?
|
| Adenine Nucleotides | 2 | 2011 | 63 | 0.370 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 112 | 0.370 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2017 | 93 | 0.360 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 84 | 0.350 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1196 | 0.350 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1458 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 559 | 0.350 |
Why?
|
| WT1 Proteins | 1 | 2009 | 19 | 0.350 |
Why?
|
| Salvage Therapy | 1 | 2010 | 233 | 0.340 |
Why?
|
| Rituximab | 4 | 2023 | 116 | 0.340 |
Why?
|
| Mice | 14 | 2016 | 11352 | 0.340 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 141 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 213 | 0.330 |
Why?
|
| Mice, Knockout | 7 | 2016 | 1924 | 0.310 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 428 | 0.290 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 17 | 0.290 |
Why?
|
| CD47 Antigen | 2 | 2016 | 13 | 0.280 |
Why?
|
| Ganciclovir | 1 | 2006 | 49 | 0.280 |
Why?
|
| Flow Cytometry | 4 | 2013 | 679 | 0.280 |
Why?
|
| Valine | 1 | 2006 | 69 | 0.270 |
Why?
|
| Peptides | 1 | 2009 | 639 | 0.270 |
Why?
|
| Acyclovir | 1 | 2006 | 107 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2007 | 510 | 0.270 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 144 | 0.260 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 286 | 0.260 |
Why?
|
| Middle Aged | 23 | 2019 | 25017 | 0.250 |
Why?
|
| Aged | 22 | 2020 | 18402 | 0.250 |
Why?
|
| Transplantation, Autologous | 4 | 2020 | 330 | 0.240 |
Why?
|
| Survival Analysis | 6 | 2017 | 1538 | 0.230 |
Why?
|
| Interferon Type I | 2 | 2016 | 175 | 0.230 |
Why?
|
| Lymphoma, Follicular | 1 | 2023 | 70 | 0.230 |
Why?
|
| Male | 25 | 2020 | 40956 | 0.230 |
Why?
|
| Self Tolerance | 2 | 2016 | 24 | 0.220 |
Why?
|
| Cell Separation | 2 | 2013 | 196 | 0.210 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 325 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 78 | 0.210 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.200 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 67 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 375 | 0.200 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2426 | 0.200 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 39 | 0.200 |
Why?
|
| Adult | 18 | 2019 | 25640 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 2232 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 49 | 0.200 |
Why?
|
| Interferon-gamma | 3 | 2013 | 444 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2016 | 425 | 0.190 |
Why?
|
| Recurrence | 4 | 2017 | 1139 | 0.190 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 5 | 0.180 |
Why?
|
| Female | 23 | 2020 | 44507 | 0.180 |
Why?
|
| Galectins | 1 | 2019 | 9 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 162 | 0.180 |
Why?
|
| Hydrazines | 1 | 2019 | 30 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 346 | 0.170 |
Why?
|
| Mitoxantrone | 1 | 2019 | 68 | 0.170 |
Why?
|
| Fetal Blood | 2 | 2017 | 90 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1197 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 1169 | 0.170 |
Why?
|
| Triazoles | 1 | 2019 | 96 | 0.170 |
Why?
|
| Cytarabine | 1 | 2019 | 218 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1313 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 120 | 0.160 |
Why?
|
| Melphalan | 2 | 2023 | 97 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 189 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2019 | 7988 | 0.150 |
Why?
|
| Clonal Anergy | 2 | 2008 | 30 | 0.150 |
Why?
|
| Remission Induction | 2 | 2017 | 722 | 0.150 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2017 | 19 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 394 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 90 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 307 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 136 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 894 | 0.140 |
Why?
|
| Xanthones | 1 | 2016 | 11 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2016 | 372 | 0.140 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 31 | 0.140 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 41 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2016 | 114 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 63 | 0.130 |
Why?
|
| Immunity | 1 | 2016 | 136 | 0.130 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 64 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2016 | 152 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 930 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 101 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 105 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 127 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 164 | 0.130 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.130 |
Why?
|
| Survival Rate | 4 | 2014 | 1860 | 0.130 |
Why?
|
| Inflammation | 1 | 2020 | 920 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1540 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 376 | 0.120 |
Why?
|
| Antigens, CD34 | 4 | 2017 | 158 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 50 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 20 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1920 | 0.120 |
Why?
|
| Interferon-beta | 1 | 2014 | 125 | 0.120 |
Why?
|
| Young Adult | 7 | 2017 | 5974 | 0.120 |
Why?
|
| Haplotypes | 2 | 2013 | 642 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2013 | 26 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 78 | 0.120 |
Why?
|
| Alemtuzumab | 3 | 2011 | 83 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 266 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 27 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2015 | 352 | 0.120 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 373 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 13 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 403 | 0.110 |
Why?
|
| Prostate | 1 | 2016 | 377 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 353 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 592 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1685 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1041 | 0.110 |
Why?
|
| Hematopoiesis | 1 | 2013 | 163 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2012 | 463 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 311 | 0.100 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 265 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 6501 | 0.100 |
Why?
|
| Cell Movement | 2 | 2016 | 758 | 0.100 |
Why?
|
| Graft Survival | 2 | 2013 | 884 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 589 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
| Hospitalization | 1 | 2016 | 848 | 0.100 |
Why?
|
| Cell Survival | 1 | 2013 | 969 | 0.090 |
Why?
|
| Incidence | 3 | 2015 | 1576 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 55 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1065 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 199 | 0.090 |
Why?
|
| Interleukin-2 | 1 | 2010 | 249 | 0.090 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 183 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 458 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 391 | 0.080 |
Why?
|
| Chimerism | 2 | 2020 | 37 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 1937 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2818 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 295 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 977 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 173 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2009 | 504 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 454 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 177 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2007 | 234 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2006 | 28 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 263 | 0.070 |
Why?
|
| Time Factors | 2 | 2013 | 5209 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 241 | 0.070 |
Why?
|
| Protein Binding | 1 | 2009 | 1456 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 269 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 3674 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1531 | 0.060 |
Why?
|
| Age Factors | 3 | 2015 | 1849 | 0.060 |
Why?
|
| Mutation | 1 | 2015 | 3967 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 839 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 547 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 154 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 8979 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5416 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 462 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1384 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 78 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 111 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 285 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4210 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1204 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 196 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 258 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 253 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 299 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 270 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 295 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 54 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2017 | 50 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 272 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 916 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 16 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 40 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2016 | 82 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 860 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 130 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 943 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 122 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 458 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 76 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 55 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 187 | 0.030 |
Why?
|
| CpG Islands | 1 | 2013 | 151 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 252 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1047 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2013 | 172 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
| Pyrazines | 1 | 2013 | 92 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 267 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 237 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 52 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 68 | 0.020 |
Why?
|
| Family | 1 | 2012 | 311 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 384 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 674 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 724 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 481 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1294 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1673 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1565 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 530 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2767 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 168 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 106 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2006 | 86 | 0.020 |
Why?
|
| Gene Library | 1 | 2006 | 130 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 393 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 196 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 150 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 689 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 776 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 528 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 1056 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 560 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1981 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1683 | 0.010 |
Why?
|